世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ヒトパピローマウイルスワクチン市場 - 世界の産業規模、シェア、動向、機会、および予測、2018年-2028年価数別(2価、4価、非価、その他)、適応疾患別(子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、その他)、流通チャネル別(病院・クリニック、政府機関・非政府機関、官民アライアンス、その他)、地域別、競争相手別


Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Region, and By Competition

ヒトパピローマウイルスワクチンの世界市場は、予測期間2024-2028年に目覚ましい成長を遂げると予測されている。ヒトパピローマウイルスウイルス関連疾患の増加、ヒトパピローマウイルスに関連する世界的な認知を... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年8月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
116 英語

 

サマリー

ヒトパピローマウイルスワクチンの世界市場は、予測期間2024-2028年に目覚ましい成長を遂げると予測されている。ヒトパピローマウイルスウイルス関連疾患の増加、ヒトパピローマウイルスに関連する世界的な認知を広めるための政府および民間組織によるイニシアチブの増加が、市場の成長を促進しています。ヒトパピローマウイルス感染症は、子宮頸がん、陰茎がん、性器がんなど、ヒトパピローマウイルス関連がんに起因する最も一般的な性感染症です。ヒトパピローマウイルスワクチンは、特定のタイプのヒトパピローマウイルスから保護する予防接種です。このワクチンは、2種類、4種類、または9種類のヒトパピローマウイルスから保護する。市場の成長を支える要因としては、治療用ワクチン開発のための研究の増加、多数の臨床試験、認知度の向上と政府投資、ヒトパピローマウイルス感染を減らすニーズの高まりなどが挙げられる。clinical trials.govによると、2022年11月現在、世界中でヒトパピローマウイルスワクチンに関連する約394の臨床研究がさまざまな開発段階にある。
ヒトパピローマウイルス疾患の症例の増加
肛門、口腔咽頭、生殖器などの異なる器官におけるヒトパピローマウイルス関連疾患の症例の急増は、ヒトパピローマウイルスワクチンの需要を著しく高め、それによって市場成長の有利な機会を生み出している。市場には、二価、四価、非価の3種類のワクチンがある。この3種類のワクチンはいずれも、子宮頸がん患者の70%を治癒させるウイルス16型と18型の感染を避けるのに非常に有効である。米国疾病予防管理センター(CDC)によると、米国ではヒトパピローマウイルスは最も一般的な性感染症である。外陰・膣疾患の70%以上、陰茎悪性腫瘍の60%、肛門癌と子宮頸部腫瘍の90%がヒトパピローマウイルスが原因である。さらに、女性の場合、子宮頸がんは9歳から30歳の間に非常に多く、HPVワクチンの必要性に拍車をかけている。例えば、WHOによると、2017年、子宮頸がんによる女性の死亡者数は世界で250万人を超え、その85%は発展途上国で発生している。
政府・民間団体による取り組みの増加
過去数年にわたり、さまざまな国の政府や民間団体は、国民の間でパピローマウイルスに関する意識を醸成するためにいくつかの措置を講じており、それによってヒトパピローマウイルスワクチン市場の成長を促進している。その結果、ヒトパピローマウイルスワクチンに関連する研究開発活動や製品の発売が増加している。例えば、最近インドでは、子宮頸がんに対する初の4価ヒトパピローマウイルスワクチン(qHPV)が発売された。また、プロフェクタス・バイオサイエンシズ社は、HPV治療ワクチンであるGeneVax prime/VesiculoVaxを開発中である。このワクチンは7種類のヒトパピローマウイルスに効果があると考えられている。さらに、ユニセフを中心とする組織は、長年にわたりワクチンの受容性を向上させる努力をしてきた。汎米保健機構(PAHO)の回転基金とユニセフの供給部門の影響により、様々な国にとって予防接種がより低価格で入手できるようになっている。
市場区分
ヒトパピローマウイルスワクチンの世界市場は、価数、適応疾患、流通チャネル、企業に区分される。価数により、市場は2価、4価、非価、その他に分けられる。適応症別では、子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、その他に分類される。販売チャネルに基づくと、市場は病院・クリニック、政府・非政府組織、公的・民間連合、その他に区分される。国別では、米国はヒトパピローマウイルス関連疾患の有病率が上昇していること、医療インフラが整備されていることから、予測期間において有利な市場になると予想される。
市場プレイヤー
Serum Institute of India Pvt. Ltd.、GlaxoSmithKline Plc.、Johnson & Johnson、Merck & Co., Inc.、AstraZeneca Plc.、Novartis AG、Inovio Pharmaceuticals, Inc.、Xenetic Biosciences, Inc.、Sanofi SA、Bharat Biotech International Limitedなどが市場で事業を展開する大手企業である。
報告書の範囲
本レポートでは、ヒトパピローマウイルスワクチンの世界市場を、業界動向に加えて、以下のカテゴリーに分類しています:
- ヒトパピローマウイルスワクチン市場、価数別
o 2価
o 4価
o 非価
o その他
- ヒトパピローマウイルスワクチン市場:適応疾患別
o 子宮頸がん
o 肛門がん
o 膣がん
o 陰茎癌
o 外陰癌
o その他
- ヒトパピローマウイルスワクチン市場:流通チャネル別
o 病院&クリニック
o 政府・非政府組織
o 公的機関および民間連合
o その他
- ヒトパピローマウイルスワクチン市場:地域別
o 北米
 米国
 カナダ
 メキシコ
o ヨーロッパ
 ドイツ
 フランス
 イギリス
 スペイン
 イタリア
o アジア太平洋
 中国
 インド
 日本
 オーストラリア
 韓国
南米
 ブラジル
 アルゼンチン
 コロンビア
o 中東・アフリカ
 南アフリカ
 サウジアラビア
 UAE
競争環境
企業プロフィール:ヒトパピローマウイルスワクチン市場に参入している主要企業の詳細分析
利用可能なカスタマイズ:
TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。このレポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場参入企業(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Patent Analysis
7. Global Human Papillomavirus Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
7.2.4. By Region
7.2.5. By Company (2022)
7.3. Market Map
7.3.1. By Valence
7.3.2. By Disease Indication
7.3.3. By Distribution Channel
7.3.4. By Region
8. North America Human Papillomavirus Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Valence
8.2.2. By Disease Indication
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Human Papillomavirus Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Valence
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By Distribution Channel
8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Valence
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By Distribution Channel
8.3.3. Canada Human Papillomavirus Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Valence
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By Distribution Channel
9. Europe Human Papillomavirus Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Valence
9.2.2. By Disease Indication
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Europe: Country Analysis
9.3.1. France Human Papillomavirus Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Valence
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By Distribution Channel
9.3.2. Germany Human Papillomavirus Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Valence
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By Distribution Channel
9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Valence
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By Distribution Channel
9.3.4. Italy Human Papillomavirus Vaccine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Valence
9.3.4.2.2. By Disease Indication
9.3.4.2.3. By Distribution Channel
9.3.5. Spain Human Papillomavirus Vaccine Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Valence
9.3.5.2.2. By Disease Indication
9.3.5.2.3. By Distribution Channel
10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Valence
10.2.2. By Disease Indication
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Human Papillomavirus Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Valence
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By Distribution Channel
10.3.2. India Human Papillomavirus Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Valence
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By Distribution Channel
10.3.3. Japan Human Papillomavirus Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Valence
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By Distribution Channel
10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Valence
10.3.4.2.2. By Disease Indication
10.3.4.2.3. By Distribution Channel
10.3.5. Australia Human Papillomavirus Vaccine Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Valence
10.3.5.2.2. By Disease Indication
10.3.5.2.3. By Distribution Channel
11. South America Human Papillomavirus Vaccine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Valence
11.2.2. By Disease Indication
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Valence
11.3.1.2.2. By Disease Indication
11.3.1.2.3. By Distribution Channel
11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Valence
11.3.2.2.2. By Disease Indication
11.3.2.2.3. By Distribution Channel
11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Valence
11.3.3.2.2. By Disease Indication
11.3.3.2.3. By Distribution Channel
12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Valence
12.2.2. By Disease Indication
12.2.3. By Distribution Channel
12.2.4. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Valence
12.3.1.2.2. By Disease Indication
12.3.1.2.3. By Distribution Channel
12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Valence
12.3.2.2.2. By Disease Indication
12.3.2.2.3. By Distribution Channel
12.3.3. UAE Human Papillomavirus Vaccine Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Valence
12.3.3.2.2. By Disease Indication
12.3.3.2.3. By Distribution Channel
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
14.1. Recent Developments
14.2. Mergers & Acquisitions
14.3. Product Launches
15. Competitive Landscape
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As reported)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Serum Institute of India Pvt. Ltd.
15.6.2. GlaxoSmithKline Plc.
15.6.3. Johnson & Johnson
15.6.4. Merck & Co., Inc.
15.6.5. AstraZeneca Plc
15.6.6. Novartis AG
15.6.7. Inovio Pharmaceuticals, Inc.
15.6.8. Xenetic Biosciences, Inc.
15.6.9. Sanofi SA
15.6.10. Bharat Biotech International Limited
16. Strategic Recommendations

 

ページTOPに戻る


 

Summary

Global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period 2024-2028. Growing incidences of Human Papillomavirus Virus-related diseases, along with the rise in initiatives by government and private organizations to spread awareness related to human papillomavirus worldwide, are augmenting the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by Human Papillomavirus Virus-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protect from certain types of human papillomavirus. It protects against either two, four, or nine kinds of Human Papillomavirus Virus. The factors supporting the market’s growth are the increasing research for the development of therapeutic vaccines, the large number of clinical trials, increasing awareness and government investments, growing need to reduce Human Papillomavirus Virus infections, among others. According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.
Increasing Cases of Human Papillomavirus Diseases
Upsurge in the cases of Human Papillomavirus related diseases in different organs such as the anal, oropharynx, and genital parts has significantly raised the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for market growth. There are just three types of vaccines in the market: bivalent, tetravalent, and nonvalent. All three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in the United States, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of Human Papillomavirus. Moreover, in women, cervical cancer is very common among those age between 9 to 30, which spurs the need for the HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer was liable for over 2,50,000 deaths of women globally, and 85% of these deaths occurred in developing countries.
Increasing Initiatives by Government & Private Organizations
Over the past few years, governments of different nations and private organizations have been taking several steps to create awareness among the population with regard to papillomavirus among the population, thereby driving the growth of the human papillomavirus vaccine market. This has, in turn, increased the research and development activities and products launched related to human papillomavirus vaccine. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in the process of developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven Human Papillomavirus kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.
Market Segmentation
Global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is categorized into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of human papillomavirus-related diseases and better healthcare infrastructure in the country.
Market Players
Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.
Report Scope:
In this report, global human papillomavirus vaccine market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Human Papillomavirus Vaccine Market, By Valence:
o Bivalent
o Quadrivalent
o Nonvalent
o Others
• Human Papillomavirus Vaccine Market, By Disease Indication:
o Cervical Cancer
o Anal Cancer
o Vaginal Cancer
o Penile Cancer
o Vulvar Cancer
o Others
• Human Papillomavirus Vaccine Market, By Distribution Channel:
o Hospitals & Clinics
o Governmental & Non-Governmental Organizations
o Public & Private Alliances
o Others
• Human Papillomavirus Vaccine Market, By Region:
o North America
 United States
 Canada
 Mexico
o Europe
 Germany
 France
 United Kingdom
 Spain
 Italy
o Asia-Pacific
 China
 India
 Japan
 Australia
 South Korea
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Human Papillomavirus Vaccine Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Patent Analysis
7. Global Human Papillomavirus Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
7.2.4. By Region
7.2.5. By Company (2022)
7.3. Market Map
7.3.1. By Valence
7.3.2. By Disease Indication
7.3.3. By Distribution Channel
7.3.4. By Region
8. North America Human Papillomavirus Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Valence
8.2.2. By Disease Indication
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Human Papillomavirus Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Valence
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By Distribution Channel
8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Valence
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By Distribution Channel
8.3.3. Canada Human Papillomavirus Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Valence
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By Distribution Channel
9. Europe Human Papillomavirus Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Valence
9.2.2. By Disease Indication
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Europe: Country Analysis
9.3.1. France Human Papillomavirus Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Valence
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By Distribution Channel
9.3.2. Germany Human Papillomavirus Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Valence
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By Distribution Channel
9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Valence
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By Distribution Channel
9.3.4. Italy Human Papillomavirus Vaccine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Valence
9.3.4.2.2. By Disease Indication
9.3.4.2.3. By Distribution Channel
9.3.5. Spain Human Papillomavirus Vaccine Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Valence
9.3.5.2.2. By Disease Indication
9.3.5.2.3. By Distribution Channel
10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Valence
10.2.2. By Disease Indication
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Human Papillomavirus Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Valence
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By Distribution Channel
10.3.2. India Human Papillomavirus Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Valence
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By Distribution Channel
10.3.3. Japan Human Papillomavirus Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Valence
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By Distribution Channel
10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Valence
10.3.4.2.2. By Disease Indication
10.3.4.2.3. By Distribution Channel
10.3.5. Australia Human Papillomavirus Vaccine Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Valence
10.3.5.2.2. By Disease Indication
10.3.5.2.3. By Distribution Channel
11. South America Human Papillomavirus Vaccine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Valence
11.2.2. By Disease Indication
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Valence
11.3.1.2.2. By Disease Indication
11.3.1.2.3. By Distribution Channel
11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Valence
11.3.2.2.2. By Disease Indication
11.3.2.2.3. By Distribution Channel
11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Valence
11.3.3.2.2. By Disease Indication
11.3.3.2.3. By Distribution Channel
12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Valence
12.2.2. By Disease Indication
12.2.3. By Distribution Channel
12.2.4. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Valence
12.3.1.2.2. By Disease Indication
12.3.1.2.3. By Distribution Channel
12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Valence
12.3.2.2.2. By Disease Indication
12.3.2.2.3. By Distribution Channel
12.3.3. UAE Human Papillomavirus Vaccine Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Valence
12.3.3.2.2. By Disease Indication
12.3.3.2.3. By Distribution Channel
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
14.1. Recent Developments
14.2. Mergers & Acquisitions
14.3. Product Launches
15. Competitive Landscape
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As reported)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Serum Institute of India Pvt. Ltd.
15.6.2. GlaxoSmithKline Plc.
15.6.3. Johnson & Johnson
15.6.4. Merck & Co., Inc.
15.6.5. AstraZeneca Plc
15.6.6. Novartis AG
15.6.7. Inovio Pharmaceuticals, Inc.
15.6.8. Xenetic Biosciences, Inc.
15.6.9. Sanofi SA
15.6.10. Bharat Biotech International Limited
16. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

TechSci Research 社の最新刊レポート

本レポートと同じKEY WORD(cancer)の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/12 10:27

160.11 円

174.44 円

209.47 円

ページTOPに戻る